Influence of parathyroid mass on the regulation of PTH secretion
|
|
- Marvin Evan Hampton
- 6 years ago
- Views:
Transcription
1 & 26 International Society of Nephrology Influence of parathyroid mass on the regulation of PTH secretion E Lewin 1,2 and K Olgaard 2 1 Nephrological Department B, The Copenhagen County Hospital in Herlev, Denmark and 2 Nephrological Department P, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark In advanced uremia, parathyroid hormone (PTH) levels should be controlled at a moderately elevated level in order to promote normal bone turnover. As such, a certain degree of parathyroid gland (PG) hyperplasia has to be accepted. No convincing evidence of apoptosis or of involution of PG hyperplasia exists. However, even considerable parathyroid hyperplasia can be controlled when the functional demand for increased PTH levels is abolished. When 2 isogenic PG were implanted into one parathyroidectomized (PTX) rat normalization of Ca 2 þ and PTH levels and normal suppressibility of PTH secretion by high Ca 2þ was obtained. Similarly, normal levels of Ca 2 þ and PTH and suppressibility of PTH secretion were obtained when Eight isogenic PG from uremic rats were implanted into normal rats or when long-term uremia and severe secondary hyperparathyroidism (sec. HPT) was reversed by an isogenic kidney transplantation. Normalization of PTH levels after experimental kidney transplantation took place despite a persistent decrease of vitamin D receptor (VDR) mrna and calcium sensing receptor (CaR) mrna in PG. Thus, in experimental models PTH levels are determined by the functional demand and not by parathyroid mass, per se. When non-suppressible sec. HPT is present in patients referred to PTX, nodular hyperplasia with differences in gene expression between different nodules has been observed in most cases. An altered expression of some autocrine/ paracrine factors has been demonstrated in the nodules. Enhanced expression of PTH-related peptide (PTHrP) has been demonstrated in PG from patients with severe secondary HPT. PTHrP has been shown to stimulate PTH secretion in vivo and in vitro. PTH/PTHrP receptor was demonstrated in the parathyroids. The low Ca 2þ stimulated PTH secretion was enhanced by 3% by PTHrP 1 4. The altered quality of the parathyroid mass and not only the increased parathyroid mass, per se, might be responsible for non-controllable hyperparathyroidism in uremia and after kidney transplantation.. doi:1.138/sj.ki KEYWORDS: PTH; secondary hyperparathyroidism; uremia; experimental hyperparathyroidism Correspondence: K Olgaard, Nephrological Department P 2132, University of Copenhagen, Rigshospitalet, 9 Blegdamsvej, Copenhagen DK-21, Denmark. olgaard@rh.dk HYPERPLASIA AND THE POSSIBILITY OF REGRESSION OF HYPERPLASIA OF THE PARATHYROID GLANDS Parathyroid tissue is a discontinuous replicator tissue, which is characterized by a low cell turnover, a low rate of mitosis, and no separate stem cells. 1,2 As estimated by Parfitt the mean life span of normal parathyroid cells is 2 years in humans and 2 years in rats. 2,3 Mitosis can be stimulated by functional demand. 4 In human subjects parathyroid growth progresses in response to chronic renal failure through several stages from diffuse hyperplasia to nodular hyperplasia and to formation of adenomas. Hyperplasia is initiated by hypocalcemia and phosphorus (P) retention and becomes more severe as the result of calcitriol deficiency. 5 Similarity exists in the gene expression between the cells in each nodule, while differences in gene expressions may be found between nodules. 6,7 Monoclonal growth of the parathyroid cells has been found in a majority of the uremic patients with refractory hyperparathyroidism. 8 The genes responsible for monoclonality have not been identified. Apparently, somatic mutations confer a growth advantage to clones of parathyroid cells, that are causing monoclonal growth and nodular parathyroid hyperplasia, although these two phenomena are not strictly linked. It seems that at the initial stages, development of parathyroid hyperplasia is a regulatory phenomenon, but that during the progression it escapes from normal growth control. The main factors responsible for parathyroid hyperplasia appear to be the same as those responsible for the enhanced parathyroid hormone (PTH) biosynthesis and secretion. The precise molecular mechanisms involved in parathyroid hyperplasia are sparsely clarified. The potential role of transforming growth factor-a, known to promote cell growth, in the parathyroid hyperplasia has been addressed Enhanced expression of transforming growth factor-a and its receptor, the epidermal growth factor receptor, occurs early after the onset of uremia in rats and is aggravated by high P or low calcium diets. 12 Furthermore, there is enhanced transforming growth factor-a expression in human hyperplastic parathyroid tissue. 13 Conversely, high dietary calcium, P restriction, and vitamin D therapy of uremic rats prevent the increase in transforming growth factor-a and induce expression of the cyclin-dependent S16
2 kinase inhibitor, p21. 9,1 Finally, female gender may favor parathyroid cell proliferation. 14 An important question is whether regression of parathyroid hyperplasia can be induced. Can the increased glandular mass seen in uremia be reduced? Such a reduction would call for massive apoptosis to take place in the parathyroids. This question has not yet been resolved. Examination for apoptosis in the parathyroids is not an easy task. 1 The parathyroids have an extremely low cell turnover, and, probably, a poorly developed program for cell deletion. The number of apoptotic cells in normal human parathyroids is very low, 1/1, parathyroid cells. 15 In rat models, several research groups have been unable to find evidence for programmed parathyroid cell death in normal or in hyperplastic parathyroid tissue. 3,16,17 Experimental studies documented that parathyroid hyperplasia is easily prevented, but poorly reversible If reversal by apoptosis takes place at all, it is probably an extremely slow process. 3 There are no known stimuli for apoptosis in the parathyroid cell, 1 although an effect of vitamin D is a possibility has not been completely excluded as such a stimulus CLINICAL VERSUS EXPERIMENTAL STUDIES OF PARATHYROID GROWTH In human studies, in general as well as in daily clinical practice evaluating parathyroid growth and glandular hyperplasia is not possible nor is it possible to obtain a biopsy of the parathyroid glands. Histological, immunohistochemical and molecular examination of parathyroid tissues from uremic patients is only available in the relatively rare situations, in which parathyroidectomy is performed. These are usually cases where hyperparathyroidism, resistant to treatment, is present in patients after years on dialysis treatment. Attempts to estimate the glandular size and nodularity, using ultrasonography, scintigraphy, and positron emission tomography scans, are also usually limited to this minority of the uremic population, in which severly increased glandular mass is present. Thus, the different stages in the development of parathyroid growth from normal glands to severe hyperplasia are not available for direct studies. We, therefore, depend upon knowledge obtained from experimental studies. In experimental models of uremia parathyroid glands are easily available and manipulation of the different factors of relevance for parathyroid growth is possible, either by dietary or pharmacological means. However, the degree of experimental uremia is usually relatively mild since more severe uremia is relatively short lasting as the rats will not survive. Nodular parathyroid hyperplasia has never been induced in animal uremic models. As such, parathyroid glands in experimental uremic animals represent diffuse chief cell hyperplasia with the exception of in a single study, where a heterogenous pattern of proliferation and expression of CaR was observed in female uremic rats kept on a high P diet. 24 This means that there is a huge gap between our ability to evaluate parathyroid hyperplasia in experimental studies and the human clinical situation. We might assume that the experimental models represent an early phase in the development of parathyroid hyperplasia in uremia, while parathyroid tissue from parathyroidectomized (PTX) patients represents the very late stage of parathyroid hyperplasia. Accepting this assumption, experimental data might provide us with important information. Parathyroid hyperplasia can be prevented by phosphate restriction, early initiation of treatment with active vitamin D analogs, or calcimimetics. 11,12,18,2,25 Established parathyroid hyperplasia can be arrested by similar initiatives, 11,12,18,2,25 and it can also be controlled by reversal of uremia. 26,27 Clinical experience has largely confirmed this assumption. Today, secondary hyperparathyroidism (sec. HPT) can be controlled in patients with long-term uremia in whom considerable parathyroid hyperplasia is to be expected. Several clinical studies have documented that PTH levels can be suppressed in most uremic patients and this suppression can be maintained by continuous treatment with phosphate binders, vitamin D analogs or calcimimetics PTH levels return, however, to pre-treatment values when the treatment is stopped. 28,29,33 This rebound of PTH levels suggest that even with good control of parathyroid function under maintainance treatment, no involution of hyperplastic glands takes place. Nevertheless, even severe HPT can be controlled in patients that previously needed PTX. 38 However, some patients remain unresponsive to treatment. 23,39,4 The long-term response to calcitriol has been reported to depend upon the size of the largest parathyroid gland. 23 This, however, does not prove that the amount of parathyroid mass by itself is decisive for the response to treatment. The quality of the increased mass might still be of significant importance for whether it is controllable by calcitriol treatment or not. Following kidney transplantation, plasma PTH will fall in most patients with sec. HPT despite previous long-term uremia. Part of this fall might be due to clearance of C-terminal PTH fragments as a result of the improvement in glomerular filtration rate (GFR), as most assays which have been used until recently co-measure some long C-terminal PTH fragments In most cases plasma PTH returns to near normal over time, although not all studies are confirmative. 44 The normalization of GFR seems, however, to be decisive for the normalization of the PTH levels In transplanted patients with reduced GFR, elevated PTH levels are found consistent with the degree of uremia and independent of the transplanted condition. Only a minority of transplanted patients requires The risk of developing post-transplant HPT increases with the duration of dialysis 49,52,53 and with the severity of the pre-transplant HPT. 46,52,54 As such, the degree of parathyroid hyperplasia is believed to determine the ability of the parathyroid glands to involute after transplantation. 55 One would expect patients requiring parathyroidectomy to PTX. 45,49 51 S17
3 have the most severe changes of the parathyroids, such as monoclonal nodular hyperplasia and formation of adenomas. Again in this situation the quality of the parathyroid mass and not only increased parathyroid mass per se might be responsible for persistent hyperparathyroidism after kidney transplantation. 56 Histological analysis of surgically removed parathyroids revealed that 9% of larger glands weighing more than.5 g were characterized by nodular hyperplasia. 57 This type of hyperplasia was shown to differ in gene expressions between nodules. 6 For example, in the same patient some nodules expressed only PTH, some both PTH and PTH-related peptide (PTHrP), while some other nodules only expressed PTHrP. 7 PTHrP has been shown by our group to be a peptide that dramatically enhances PTH secretion in response to hypocalcemia in normal as well as in uremic rats, 58,59 (Figure 1). As such, altered expression and regulation of paracrine/autocrine factors in different nodules might be responsible for the finding that the PTH secretion from the increased parathyroid mass cannot be controlled. Another important aspect in evaluating parathyroid hyperplasia in animal models and in human parathyroid glands is the different cellular composition of the glands. Normal human glands contain different cell types, chief cells, and oxyphilic cells, while rat glands consist only of chief cells. 6 Traditionally, parathyroid oxyphilic cells have been regarded as having no specific function, at least no known function. However, oxyphilic adenomas have been shown to be functional and the cells contained PTH and/or PTHrP In normal human glands oxyphilic cells have a sparse diffuse distribution, while multiple nodules consisting of oxyphilic cells have been found in parathyroid hyperplasia. These nodules expressed enhanced cyclooxygenase-2 reactivity, besides expressing PTHrP. 6,64 As such, nodular hyperplasia in human parathyroid glands might have additional regulatory mechanisms, as compared to rodent glands. CONTROL OF INCREASED PARATHYROID MASS An important observation from several experimental studies on sec. HPT is, that the increased proliferation of parathyroid cells, which is induced by uremia, can be arrested. Administration of calcium-sensing receptor agonists (calcimimetics), calcitriol, or low P diet have led to suppression of parathyroid cell proliferation in uremic rats. 11,12,18,2,25 This creates a possibility for controlling the degree or severity of the increase in parathyroid mass in uremia. Furthermore, it has been shown that PTH secretion from increased parathyroid mass could be controlled, according to the functional demand. In two models of parathyroid hyperplasia, 2 normal, isogenic parathyroid glands or eight isogenic parathyroid glands from uremic rats were implanted into one normal recipient rat after removal of its own two parathyroid glands 27,65 (the rat only has two glands) (Figure 2). A transient period of hypercalcemia occurred initially after the increase of the parathyroid mass. Within 2 weeks, however, plasma calcium returned to normal levels and remained normal for the following 6 weeks of observation. PTH levels became normal from the 3rd day after implantation of the 2 parathyroid glands and remained normal for the following 6 weeks. 27 The important observations from these two models of parathyroid hyperplasia are that both calcium and PTH levels eventually became normal and that this normalization took place whether the increased parathyroid mass consisted of normal or uremic parathyroid glands. 27 Subsequently, parathyroid function was examined and normal suppressibility of PTH secretion by calcium was demonstrated in the rats with 2 parathyroid glands implanted (1 times increased parathyroid mass). 27 In another model we showed that the functional demand determines PTH levels in uremic animals whether they have two or eight parathyroid glands present. Thus, PTH levels of 5/6 nephrectomized rats, uremic for 8 weeks and kept on a high P diet, were severely increased. Then the rat s two parathyroid glands were removed and eight isogenic parathyroid glands were implanted into each rat. After implantation of eight glands, and during the same uremic condition, the rat developed exactly the same level of sec. HPT with PTH levels at around 8 pg/ml. Thus, persisting functional demand reintroduced the same degree of hyperparathyroidism in rats with eight glands as in rats with two glands. 27 In another set of experiments two uremic hyperplastic glands were implanted into a normal PTX rat. One week later these rats had normal PTH levels, similar to that of normal control rats. In the following 4 weeks the rats were challenged with a diet of high P and low calcium. This change in the functional demand resulted in completely the same increase in PTH secretion from uremic hyperplastic glands, as seen from normal glands of control rats. 27 a PTH, pg/ml PTHrP 1-4 PTHrP 1-86 Control Minutes b Ca 2+ mmol/l Minutes Figure 1 Expression of autocrine/paracrine factors might modulate parathyroid function. (a b) Enhanced expression of PTHrP has been demonstrated in glands from patients with severe sec. HPT due to uremia. PTH/PTHrP receptor was demonstrated in the parathyroids. This figure shows the effect of N-terminal PTHrP on the secretory response of PTH to an acute induction of hypocalcemia in the rat. The rate of reduction of plasma-ca 2 þ by an ethyleneglycol-bis(b-aminoethyl ether) N,N,N,N -tetraacetic acid (EGTA) infusion was similar in all groups of rats. A bolus of PTHrP 1 4, PTHrP 1 86, or vehicle was injected at time. PTHrP significantly enhanced by 3% (Po.1) the low-ca 2 þ -stimulated PTH secretion in vivo. N ¼ 6 in each group, mean7s.e.m. Modified from Lewin et al. 58 S18
4 In another model, 27 severe sec. HPT, due to long-term uremia and associated with hypocalcemia and hyperphosphatemia, was rapidly reversed after reversal of uremia by an experimental, isogenic kidney transplantation (Figure 3). The circulating levels of PTH became normal within 1 week after normalization of GFR, plasma calcium, and plasma P levels. The precise mechanism behind this rapid reversal of sec. HPT after normalization of GFR is not completely clarified. CaR and VDR mrna were reduced in parathyroid glands obtained from uremic rats with severe sec. HPT. The dramatic decrease of PTH secretion following reversal of uremia by kidney transplantation, occurred however with unchanged and significantly diminished expression of the CaR and VDR genes in the parathyroid glands. 26 Circulating levels of PTH increased 2-fold in uremic rats given a high P diet, while the CaR mrna levels decreased by approximately 6%. Four to 8 days after kidney transplantation PTH levels became normal, despite a persistence of very low expression of CaR mrna, similar to that of uremic rats. Thus, to our surprise, the rapid normalization of circulating PTH levels after transplantation was not associated with normalization of the parathyroid CaR gene expression. This might indicate the existence of a secretory mechanism in parathyroid cells that is not coupled to CaR and which responds to reversal of uremia or to the simultaneous normalization of plasma Ca 2 þ and P levels. Similarly, results of Tagahashi from Dr Slatopolsky s group pointed towards a potent mechanism controlling exocytosis of PTH from hyperplastic parathyroid glands. They studied the PTH levels in uremic rats after 2 weeks of high dietary P and then examined the conditions after 1 further week on a low P intake. The glandular mass was significantly increased and PTH levels were significantly elevated when the rats were on a high P diet. After switching to a low P diet, parathyroid mass was still increased, but despite that the PTH levels were significantly reduced. Then, they looked upon the cytosolic Plasma Ca 2+, mmol/l * * * * * Days after implantation of 2 parathyroid glands Figure 2 Even considerable parathyroid hyperplasia can be controlled in the normal organism. When 2 isogenic parathyroid glands were implanted into one PTX rat a short-lasting hypercalcemia was induced, soon followed, however, by normalization of Ca 2 þ and PTH levels. This figure shows plasma Ca 2 þ and plasma PTH levels in rats with 2 isogenic parathyroid glands implanted. Parathyroidectomy of their own parathyroid glands was performed on day, before the implantation of the 2 glands. The line ( ) depicts plasma Ca 2 þ levels, while the bars depict PTH levels. N ¼ 6, mean7s.e.m. *Po.5 versus the level at day, before PTX. Modified from Lewin et al Plasma PTH, pg/ml PTH content and found that PTH content in these huge parathyroid glands was still elevated. As such normalization of PTH secretion in response to low P occured, despite persistently increased glandular mass, and despite increased amount of PTH in the secretory granules. This observation indicates, that there is a potent secretory mechanism controlling increased glandular mass. 66 Plasma urea, mmol/l TX Weeks of uremia and after transplantation (TX) 1 Figure 3 Severe parathyroid hyperplasia can be controlled when the functional demand for increased PTH levels is abolished by normalization of the kidney function. This figure shows kidney function and basal PTH levels before introduction of uremia by 5/6 nephrectomy ( 2 weeks), during uremia ( 2 to weeks), and after reversal of uremia by an isogenic kidney transplantation (TX). The lines ( ) depict kidney function expressed as plasma urea and the bars depict PTH levels. The uremic rats were kept on a high P diet. N ¼ 12, mean7s.e.m. Modified from Lewin et al. 27 PTH, pg/ml Uremia-P TX Controls Ca 2+, mmol/l Figure 4 Suppressibility of PTH secretion by Ca 2 þ is not influenced by the parathyroid mass, itself. Parathyroid function was investigated by the Ca 2 þ /PTH relationship during acute inductions of hypocalcemia and hypercalcemia in uremic rats kept on high P diet (Uremia-P), kidney transplanted, 3 weeks after transplantation (TX), and in normal control rats (controls). The PTH secretory response to hypocalcemia was significantly higher in uremic rats (Po.1) than in kidney transplanted and normal control rats. The PTH secretion was suppressed to same extend in kidney transplanted rats and normal control rats, while uremic hyperphosphatemic rats had a significantly higher (Po.5) PTH secretion at high Ca 2 þ. N ¼ 6, mean7s.e.m. Modified from Lewin et al. 27 Plasma PTH, pg/ml S19
5 CaR mrna/ actin mrna % of control 3 * 2 1 * Control CRF hp TX 1 w In uremic hyperphosphatemic rats high plasma calcium did not suppress PTH secretion to the same extent as seen in normal and uremic, normophosphatemic rats. Three weeks after an experimental kidney transplantation normal suppressibility of PTH secretion by calcium was, however, restored 27 (Figure 4). When the parathyroid CaR gene expression was examined at 4 weeks after experimental kidney transplantation, the expression was upregulated (Figure 5), indicating that CaR expression is regulated according to the functional demand for PTH secretion, although this regulation is rather slow. These results clearly demonstrate that even considerable parathyroid hyperplasia can be controlled when the functional demand for increased PTH levels is abbolished by normalization of GFR, plasma calcium, and plasma P levels. CONCLUSION PTH secretion can be controlled in normal rats despite considerably increased parathyroid mass, consisting of normal glands or uremic glands. In uremia, increased PTH secretion is regulated by increased functional demand for PTH due to hypocalcemia, P retention, decreased 1ahydroxylase activity, skeletal resistance, and other factors. PTH secretion depends upon and responds to changes in functional demand, independently of the parathyroid mass. In patients with long-term severe uremia extreme heterogenicity of gene and protein expression develops in nodular parathyroid hyperplasia. PTH secretion might be affected by autocrine/paracrine factors, for example PTHrP. The expression of such factors in the different noduli might be of importance for the increased PTH secretion in nodular parathyroid hyperplasia. The parathyroid mass is to a large extent of less importance for PTH secretion than the quality of parathyroid mass. The content of the different noduli in severe parathyroid hyperplasia is determining the PTH secretion. * TX 4 w Figure 5 Upregulation of the parathyroid CaR gene expression after reversal of uremia by kidney transplantation (TX) does not occur immediately. The expression of CaR was still diminished 1 week after TX, at a time when circulating PTH levels already were normalized. The figure shows the CaR gene expression in the parathyroid glands of normal control rats, uremic rats on a high P diet (CRF hp), and kidney transplanted (TX), 1 and 4 weeks after kidney transplantation. N ¼ 5 8, mean7s.e.m. *Po.1 versus control rats. REFERENCES 1. Drueke TB. Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol 2; 11: Parfitt AM. The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 1997; 52: Wang Q, Palnitkar S, Parfitt AM. Parathyroid cell proliferation in the rat: effect of age and of phosphate administration and recovery. Endocrinology 1996; 137: Tominaga Y, Takagi H. Molecular genetics of hyperparathyroid disease. Curr Opin Nephrol Hypertens 1996; 5: Rodriguez M, Canalejo A, Garfia B et al. Pathogenesis of refractory secondary hyperparathyroidism. Kidney Int 22; 61(Suppl 8): Valimaki S, Farnebo F, Forsberg L et al. Heterogeneous expression of receptor mrnas in parathyroid glands of secondary hyperparathyroidism. Kidney Int 21; 6: Matsushita H, Hara M, Endo Y et al. Proliferation of parathyroid cells negatively correlates with expression of parathyroid hormone-related protein in secondary parathyroid hyperplasia. Kidney Int 1999; 55: Arnold A, Brown MF, Urena P et al. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 1995; 95: Dusso AS, Pavlopoulos T, Naumovich L et al. p21(waf1) and transforming growth factor-alpha mediate dietary phosphate regulation of parathyroid cell growth. Kidney Int 21; 59: Cozzolino M, Lu Y, Finch J et al. p21waf1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int 21; 6: Cozzolino M, Brancaccio D, Gallieni M et al. Pathogenesis of parathyroid hyperplasia in renal failure. J Nephrol 25; 18: Cozzolino M, Lu Y, Sato T et al. A Critical role for enhanced-tgf{alpha} and EGFR Expression in the initiation of parathyroid hyperplasia in experimental kidney disease. Am J Physiol Renal Physiol 25; 289: F196 F Gogusev J, Duchambon P, Stoermann-Chopard C et al. De novo expression of transforming growth factor-alpha in parathyroid gland tissue of patients with primary or secondary uraemic hyperparathyroidism. Nephrol Dial Transplant 1996; 11: Almaden Y, Felsenfeld AJ, Rodriguez M et al. Proliferation in hyperplastic human and normal rat parathyroid glands: role of phosphate, calcitriol, and gender. Kidney Int 23; 64: Zhang P, Duchambon P, Gogusev J et al. Apoptosis in parathyroid hyperplasia of patients with primary or secondary uremic hyperparathyroidism. Kidney Int 2; 57: Naveh-Many T, Rahamimov R, Livni N, Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest 1995; 96: Wada M, Furuya Y, Sakiyama Ji et al. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 1997; 1: Szabo A, Merke J, Beier E et al. 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989; 35: Yi H, Fukagawa M, Yamato H et al. Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible direct role of phosphorus. Nephron 1995; 7: Colloton M, Shatzen E, Miller G et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 25; 67: Henry HL, Taylor AN, Norman AW. Response of chick parathyroid glands to the vitamin D metabolites, 1,25-dihydroxycholecalciferol and 24,25-dihydroxycholecalciferol. J Nutr 1977; 17: Fukagawa M, Okazaki R, Takano K et al. Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. N Engl J Med 199; 323: Fukagawa M, Kitaoka M, Yi H et al. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron 1994; 68: Brown AJ, Ritter CS, Finch JL, Slatopolsky EA. Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphate. Kidney Int 1999; 55: Wada M, Nagano N, Furuya Y et al. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 2; 57: S2
6 26. Lewin E, Garfia B, Recio FL et al. Persistent downregulation of calcium-sensing receptor mrna in rat parathyroids when severe secondary hyperparathyroidism is reversed by an isogenic kidney transplantation. J Am Soc Nephrol 22; 13: Lewin E, Wang W, Olgaard K. Reversibility of experimental secondary hyperparathyroidism. Kidney Int 1997; 52: Chertow GM, Dillon M, Burke SK et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 1999; 51: Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int 1999; 55: Brandi L, Daugaard H, Tvedegaard E et al. Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis. Nephron 1989; 53: Martin KJ, Gonzalez EA, Gellens M et al. 19-Nor-1-alpha-25- dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9: Akizawa T, Suzuki M, Akiba T et al. Clinical effects of maxacalcitol on secondary hyperparathyroidism of uremic patients. Am J Kidney Dis 21; 38: S147 S Akiba T, Marumo F, Owada A et al. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1998; 32: Hamdy NA, Kanis JA, Beneton MN et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995; 31: Rapoport J, Mostoslavski M, Ben David A et al. Successful treatment of secondary hyperparathyroidism in hemodialysis patients with oral pulse 1-alpha-hydroxy-cholecalciferol therapy. Nephron 1996; 72: Coburn JW, Maung HM, Elangovan L et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 24; 43: Lindberg JS, Moe SM, Goodman WG et al. The calcimimetic AMG 73 reduces parathyroid hormone and calcium phosphorus in secondary hyperparathyroidism. Kidney Int 23; 63: Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 24; 35: Gallieni M, Brancaccio D, Padovese P et al. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol. Kidney Int 1992; 42: Schindler S, Mannstadt M, Urena P et al. PTH secretion in patients with chronic renal failure assessed by a modified CiCa clamp method: effects of 1-year calcitriol therapy. Clin Nephrol 24; 61: Brossard JH, Cloutier M, Roy L et al. Accumulation of a non-(1 84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab 1996; 81: Nguyen-Yamamoto L, Rousseau L, Brossard JH et al. Origin of parathyroid hormone (PTH) fragments detected by intact-pth assays. Eur.J Endocrinol 22; 147: Lepage R, Roy L, Brossard JH et al. A non-(1 84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998; 44: Dumoulin G, Hory B, Nguyen NU et al. No trend toward a spontaneous improvement of hyperparathyroidism and high bone turnover in normocalcemic long-term renal transplant recipients. Am J Kidney Dis 1997; 29: Reinhardt W, Bartelworth H, Jockenhovel F et al. Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant 1998; 13: Botha JF, Botha JR. Parathyroid function after successful renal transplantation. S Afr J Surg 1997; 35: Claesson K, Hellman P, Frodin L, Rastad J. Prospective study of calcium homeostasis after renal transplantation. World J Surg 1998; 22: Uchida K, Tominaga Y, Tanaka Y, Takagi H. Renal transplantation and secondary hyperparathyroidism. Semin Surg Oncol 1997; 13: D Alessandro AM, Melzer JS, Pirsch JD et al. Tertiary hyperparathyroidism after renal transplantation: operative indications. Surgery 1989; 16: Parfitt AM. Hypercalcemic hyperparathyroidism following renal transplantation: differential diagnosis, management, and implications for cell population control in the parathyroid gland. Miner Electrolyte Metab 1982; 8: Schmid T, Muller P, Spelsberg F. Parathyroidectomy after renal transplantation: a retrospective analysis of long-term outcome. Nephrol Dial Transplant 1997; 12: Messa P, Sindici C, Cannella G et al. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 1998; 54: Kinnaert P, Nagy N, Decoster-Gervy C et al. Persistent hyperparathyroidism requiring surgical treatment after kidney transplantation. World J Surg 2; 24: Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol 22; 13: McCarron DA, Muther RS, Lenfesty B, Bennett WM. Parathyroid function in persistent hyperparathyroidism: relationship to gland size. Kidney Int 1982; 22: Lewin E. Involution of the parathyroid glands after renal transplantation. Curr Opin Nephrol Hypertens 23; 12: Tominaga Y, Sato K, Tanaka Y et al. Histopathology and pathophysiology of secondary hyperparathyroidism due to chronic renal failure. Clin Nephrol 1995; 44(Suppl 1): S42 S Lewin E, Almaden Y, Rodriguez M, Olgaard K. PTHrP enhances the secretory response of PTH to a hypocalcemic stimulus in rat parathyroid glands. Kidney Int 2; 58: Lewin E, Garfia B, Almaden Y et al. Autoregulation in the parathyroid glands by PTH/PTHrP receptor ligands in normal and uremic rats. Kidney Int 23; 64: Bell CD, Vidal S, Kovacs K et al. Cox-2 expression in the oxyphilic cells of the normal, hyperplastic, and adenomatous parathyroid gland. Endocr Pathol 24; 15: Finch JL, Dusso AS, Pavlopoulos T, Slatopolsky EA. Relative potencies of 1,25-(OH)(2)D(3) and 19-Nor-1,25-(OH)(2)D(2) on inducing differentiation and markers of bone formation in MG-63 cells. J Am Soc Nephrol 21; 12: Bedetti CD, Dekker A, Watson CG. Functioning oxyphil cell adenoma of the parathyroid gland: a clinicopathologic study of ten patients with hyperparathyroidism. Hum Pathol 1984; 15: Ordonez NG, Ibanez ML, Mackay B et al. Functioning oxyphil cell adenomas of parathyroid gland: immunoperoxidase evidence of hormonal activity in oxyphil cells. Am J Clin Pathol 1982; 78: Matsushita H, Usui M, Hara M et al. Co-secretion of parathyroid hormone and parathyroid-hormone-related protein via a regulated pathway in human parathyroid adenoma cells. Am J Pathol 1997; 15: Lewin E. Parathyroid hormone regulation in normal and uremic rats. Reversibility of secondary hyperparathyroidism after experimental kidney transplantation. Dan Med Bull 24; 51: Takahashi F, Denda M, Finch JL et al. Hyperplasia of the parathyroid gland without secondary hyperparathyroidism. Kidney Int 22; 61: S21
Secondary hyperparathyroidism an Update on Pathophysiology and Treatment
Secondary hyperparathyroidism an Update on Pathophysiology and Treatment Klaus Olgaard Copenhagen Budapest Nephrology School August 2007 HPT IN CRF Renal mass Ca 2+ 1,25(OH) 2 D 3 CaR Hyperparathyroidism
More informationRenal osteodystrophy with special emphasis on secondary hyperparathyroidism
RENAL OSTEODYSTROPHY WITH SPECIAL EMPHASIS ON SECONDARY HYPERPARATHYROIDISM Artigo Original Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 9-18 Renal osteodystrophy with special emphasis on secondary hyperparathyroidism
More informationEffect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients
Nephrol Dial Transplant (2003) 18 [Suppl 3]: iii42 iii46 DOI: 10.1093/ndt/gfg1011 Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients Kazuhiro Shiizaki
More informationTherapeutic golas in the treatment of CKD-MBD
Therapeutic golas in the treatment of CKD-MBD Hemodialysis clinic Clinical University Center Sarajevo Bantao, 04-08.10.2017, Sarajevo Abbvie Satellite symposium 06.10.2017 Chronic Kidney Disease Mineral
More informationCKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow
CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker
More informationBasic and clinical aspects of parathyroid hyperplasia in chronic kidney disease
http://www.kidney-international.org & 2006 International Society of Nephrology Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease M Fukagawa 1, S Nakanishi 1 and JJ Kazama
More informationDo We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital
Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker
More informationA calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure Rapid Communication
Kidney International, Vol. 53 (1998), pp. 223 227 A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure Rapid Communication JOHN E. ANTONSEN, DONALD
More informationHyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012
Hyperparathyroidism: Operative Considerations Financial Disclosures: None Steven J Wang, MD FACS Associate Professor Dept of Otolaryngology-Head and Neck Surgery University of California, San Francisco
More informationThe role of calcimimetics in chronic kidney disease
http://www.kidney-international.org & 2006 International Society of Nephrology The role of calcimimetics in chronic kidney disease A Gal-Moscovici 1,2 and SM Sprague 1 1 Division of Nephrology and Hypertension,
More informationTitle:Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism
Author's response to reviews Title:Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism Authors: Li Fang (fangli@njmu.edu.cn)
More informationPersistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019
Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal
More informationThis review examines the dynamics of parathyroid hormone
In-Depth Review Dynamics of Parathyroid Hormone Secretion in Health and Secondary Hyperparathyroidism Arnold J. Felsenfeld,* Mariano Rodríguez, and Escolástico Aguilera-Tejero *Department of Medicine,
More informationKobe University Repository : Kernel
Title Author(s) Citation Issue date 2009-09 Resource Type Resource Version DOI URL Kobe University Repository : Kernel Marked increase in bone formation markers after cinacalcet treatment by mechanisms
More informationCell Biology of Parathyroid Gland Hyperplasia in Chronic Renal Failure
REVIEW J Am Soc Nephrol 11: 1141 1152, 2000 Cell Biology of Parathyroid Gland Hyperplasia in Chronic Renal Failure TILMAN B. DRÜEKE Institut National de la Santé et de la Recherche Médicale U507 and Division
More informationPathogenesis of secondary hyperparathyroidism
The International Journal of Artificial Organs / Vol. 32 / no. 2, 2009 / pp. 75-80 Review Pathogenesis of secondary hyperparathyroidism MARIO COZZOLINO, SABINA PASHO, GIUDITTA FALLABRINO, LAURA OLIVI,
More informationHyperphosphatemia Modestly Retards Parathyroid Hormone Suppression during Calcitriol-Induced Hypercalcemia in Normal and Azotemic Rats
Original Paper Nephron 2002;92:883 888 DOI: 10.1159/000065454 Accepted: May 22, 2002 Hyperphosphatemia Modestly Retards Parathyroid Hormone Suppression during Calcitriol-Induced Hypercalcemia in Normal
More informationSecondary Hyperparathyroidism: Where are we now?
Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused
More informationMarie-Claude Monier-Faugere, Hanna Mawad, and Hartmut H. Malluche
Opposite Effects of Calcitriol and Paricalcitol on the Parathyroid Hormone-(1-84)/Large Carboxy-Terminal- Parathyroid Hormone Fragments Ratio in Patients with Stage 5 Chronic Kidney Disease Marie-Claude
More informationAbnormal calcaemic response to PTH in the uraemic rat without secondary hyperparathyroidism
Nephrol Dial Transplant (1996) 11: 1292-1298 Original Article Mephrology Dialysis Transplantation Abnormal calcaemic response to PTH in the uraemic rat without secondary hyperparathyroidism. Berdud, A.
More information( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes
..., 2013 Amgen. 1 ? ( ), (Donabedian, 1980) We would not choose any treatment with poor outcomes 1. :, 2. ( ): 3. :.,,, 4. :, [Biomarkers Definitions Working Group, 2001]., (William M. Bennet, Nefrol
More informationVitamin D Receptor and Analogs
Vitamin D Receptor and Analogs By Adriana S. Dusso,* Ravi Thadhani, and Eduardo Slatopolsky* In chronic kidney disease (CKD), high circulating levels of parathyroid hormone (PTH) cause osteitis fibrosa,
More informationHYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY
UK RENAL PHARMACY GROUP SUBMISSION TO THE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE on CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE
More informationMedical and surgical aspects of parathyroidectomy
Kidney International, Vol. 56, Suppl. 73 (1999), pp. S-65 S-69 Medical and surgical aspects of parathyroidectomy MASAFUMI FUKAGAWA, YOSHIHIRO TOMINAGA, MASAFUMI KITAOKA, TAKATOSHI KAKUTA, and KIYOSHI KUROKAWA
More informationThe Parsabiv Beginner s Book
The Parsabiv Beginner s Book A quick guide to help you learn about your treatment with Parsabiv and what to expect Indication Parsabiv (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism
More informationRenal Osteodystrophy. Chapter 6. I. Introduction. Classification of Bone Disease. Eric W. Young
Chapter 6 Renal Osteodystrophy Eric W. Young I. Introduction Renal osteodystrophy refers to bone disease that occurs in patients with kidney disease. Bone disease occurs across the full spectrum of kidney
More informationSensipar. Sensipar (cinacalcet) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.46 Subject: Sensipar Page: 1 of 5 Last Review Date: June 22, 2018 Sensipar Description Sensipar (cinacalcet)
More informationUltrasound examination in diagnosis of morphological variants of parathyroid hyperplasia in patients with secondary hyperparathyroidism
Ultrasound examination in diagnosis of morphological variants of parathyroid hyperplasia in patients with secondary hyperparathyroidism Poster No.: C-0304 Congress: ECR 2015 Type: Authors: Keywords: DOI:
More informationControl of parathyroid cell growth by calcimimetics
Nephrol Dial Transplant (2003) 18 [Suppl 3]: iii13 iii17 DOI: 10.1093/ndt/gfg1004 Control of parathyroid cell growth by calcimimetics Michihito Wada and Nobuo Nagano Pharmaceutical Development Laboratories,
More informationNew vitamin D analogs
Kidney International, Vol. 63, Supplement 85 (2003), pp. S83 S87 New vitamin D analogs EDUARDO SLATOPOLSKY, JANE FINCH, and ALEX BROWN Renal Division, Department of Internal Medicine, Washington University
More informationDevelopment and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics
translational nephrology http://www.kidney-international.org & 2008 International Society of Nephrology Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from
More informationThe role of vitamin D in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure
The role of vitamin D in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure Mini-review Giuseppe Vezzoli 1 Teresa Arcidiacono 1 Mario Cozzolino 2 1 Nephrology Unit,
More informationShould cinacalcet be used in patients who are not on dialysis?
Should cinacalcet be used in patients who are not on dialysis? Jorge B Cannata-Andía and José Luis Fernández-Martín Affiliations: Bone and Mineral Research Unit. Hospital Universitario Central de Asturias.
More informationDifferent effects of calcitriol and parathytoidectomy on the PTH-calcium curve in dialysis patients with severe hyperparathyroidism
Nephrol Dial Transplant (996) : 8-87 Original Article Nephrology Dialysis Transplantation Different effects of calcitriol and parathytoidectomy on the PTH-calcium curve in dialysis patients with severe
More information02/27/2018. Objectives. To Replace or Not to Replace: Nutritional Vitamin D in Dialysis.
To Replace or Not to Replace: Nutritional Vitamin D in Dialysis. Michael Shoemaker-Moyle, M.D. Assistant Professor of Clinical Medicine Objectives Review Vitamin D Physiology Review Current Replacement
More informationTitle:Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism
Author's response to reviews Title:Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism Authors: Li Fang (fangli@njmu.edu.cn)
More informationConsiderations for the Treatment of Secondary Hyperparathyroidism in Renal Failure
DISEASEOF THE MONTH Considerations for the Treatment of Secondary Hyperparathyroidism in Renal Failure ARNOLD J. FELSENFELD Department of Medicine, West Los Angeles Veterans Affairs Medical Center, and
More informationchapter 1 & 2009 KDIGO
http://www.kidney-international.org chapter 1 & 2009 DIGO Chapter 1: Introduction and definition of CD MBD and the development of the guideline statements idney International (2009) 76 (Suppl 113), S3
More informationRenal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD
Nephron Clin Pract 2011;118(suppl 1):c145 c152 DOI: 10.1159/000328066 Received: May 24, 2010 Accepted: December 6, 2010 Published online: May 6, 2011 Renal Association Clinical Practice Guideline in Mineral
More informationAmol K Choulwar et al. / Journal of Pharmacy Research 2012,5(1), Available online through
Research Article ISSN: 0974-6943 Amol K Choulwar et al. / Journal of Pharmacy Research 2012,5(1), Available online through www.jpronline.info Comparison of efficacy and safety of Cinacalcet versus Calcitriol
More informationThe impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure
Nephrol Dial Transplant (2002) 17: 340 345 The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure Naseem Amin Genzyme Corporation, Cambridge, MA,
More informationOutline. The Role of Vitamin D in CKD. Essential Role of Vitamin D. Mechanism of Action of Vit D. Mechanism of Action of Vit D 7/16/2010
Outline The Role of Vitamin D in CKD Priscilla How, Pharm.D., BCPS Assistant Professor National University of Singapore Principal Clinical Pharmacist National University Hospital (Pharmacy and Nephrology,
More informationPathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention
NDT Plus (2008) 1 [Suppl 3]: iii2 iii8 doi: 10.1093/ndtplus/sfn079 Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention Shunsuke
More informationChapter 5: Evaluation and treatment of kidney transplant bone disease Kidney International (2009) 76 (Suppl 113), S100 S110; doi: /ki.2009.
http://www.kidney-international.org & 2009 KDIGO Chapter 5: Evaluation and treatment of kidney transplant bone disease ; doi:10.1038/ki.2009.193 Grade for strength of recommendation a Strength Wording
More informationTechnetium-99m Sestamibi Scintigraphy Pattern in Patients with Secondary Hyperparathyroidism
. 2009 May;2(2):16-20 Original Article AJNT Technetium- Sestamibi Scintigraphy Pattern in Patients with Secondary Hyperparathyroidism Ahmed A Kandeel a*, Mohamed A Hawary b and Hisham S Ebaid c a Oncology
More informationSURGERY FOR RENAL HYPERPARATHYROIDISM - EXPERIENCE OF 640 CASES -
Nagoya J. Med. Sci. 60. 15-22, 1997 INVITED REVIEW ARTICLE SURGERY FOR RENAL HYPERPARATHYROIDISM - EXPERIENCE OF 640 CASES - HIROSHI TAKAGI,* YOSHIHIRO TOMINAGA,** Yun TANAKA,* and KAZUHARU UCHIDA** 'Department
More informationSensipar (cinacalcet)
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationProliferation in hyperplastic human and normal rat parathyroid glands: Role of phosphate, calcitriol, and gender
Kidney International, Vol. 64 (2003), pp. 2311 2317 Proliferation in hyperplastic human and normal rat parathyroid glands: Role of phosphate, calcitriol, and gender YOLANDA ALMADEN, ARNOLD J. FELSENFELD,
More informationCinacalcet suppresses calcification of the aorta and heart in uremic rats
original article http://www.kidney-international.org & 28 International Society of Nephrology see commentary on page 1229 Cinacalcet suppresses calcification of the aorta and heart in uremic rats Takehisa
More informationPhosphate and the parathyroid
translational nephrology http://www.kidney-international.org & 2009 International Society of Nephrology Phosphate and the parathyroid Justin Silver 1 and Tally Naveh-Many 1 1 Minerva Center for Calcium
More informationCase Report Use of Percutaneous Ethanol Injection Therapy for Recurrent Secondary Hyperparathyroidism after Subtotal Parathyroidectomy
SAGE-Hindawi Access to Research International Nephrology Volume 211, Article ID 246734, 6 pages doi:1.461/211/246734 Case Report Use of Percutaneous Ethanol Injection Therapy for Recurrent Secondary Hyperparathyroidism
More informationKey words: Vitamin D analogues, alfacalcidol, calcitriol, secondary hyperparathyroidism, renal dialysis
Oral cal ORAL CALCITRIOL VERSUS ORAL ALFACALCIDOL FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS RECEIVING HEMODIALYSIS: A RANDOMIZED, CROSSOVER TR IAL Samantha Moe 1, Lori D Wazny 2, Janet
More informationGuidelines for dosing of intravenous calcitriol in dialysis patients with hyperparathyroidism
Nephrol Dial Transplant (16) 11 [Suppl 3]: 6-101 Nephrology Dialysis Transplantation Guidelines for dosing of intravenous calcitriol in dialysis patients with hyperparathyroidism E. Fernandez 1 and F.
More informationPathogenesis and Treatment of Renal Osteodystrophy
Proceedings Blood Purif 2003;21:318 326 DOI: 10.1159/000072552 Eduardo Slatopolsky a Esther Gonzalez b Kevin Martin b a Renal Division, Washington University School of Medicine, St. Louis, Mo., and b Division
More informationCa, Phos and Vitamin D Metabolism in Pre-Dialysis Patients
Ca, Phos and Vitamin D Metabolism in Pre-Dialysis Patients A. WADGYMAR, MD Credit Valley Hospital, Mississauga, Ontario, Canada. June 1, 2007 1 Case: 22 y/o referred to Renal Clinic Case: A.M. 29 y/o Man
More informationhypercalcemia of malignancy hyperparathyroidism PHPT the most common cause of hypercalcemia in the outpatient setting the second most common cause
hyperparathyroidism A 68-year-old woman with documented osteoporosis has blood tests showing elevated serum calcium and parathyroid hormone (PTH) levels: 11.2 mg/dl (8.8 10.1 mg/dl) and 88 pg/ml (10-60),
More information... . : ... PTH.
IRMA Email msarookhani@qumsacir * CRD GFR D [1,25OH 2 D 3 ] SHPT GFR» «KDOQI SHPT Ca * P P P Selectra Overt HPT = = Ca * P P > GM II DSL i IRMA ± ± ± Ca * P % % % % % % % % % % % % % % % % pgml = = > ±
More information2017 KDIGO Guidelines Update
2017 KDIGO Guidelines Update Clinic for Hemodialysis Clinical Center University of Sarajevo 13 th Congress of the Balkan cities Association of Nephrology, Dialysis, and Artificial Organs Transplantation
More informationin chronic renal failure
Kidney International, Vol. 48 (1995), pp. 259 2 72 NEPHROLOGY FORUM The pathogenesis of parathyroid gland hyperplasia in chronic renal failure Principal discussant: TILMAN B. DRUEKE Hôpital Necker, Paris,
More informationParathyroid Hormone, Calcium and Phosphorus Levels in Hemodialysis Patients at Al-Shifa Hospital, Gaza-Palestine
IUG Journal of Natural and Engineering Studies Vol.22,No.1, pp 97-110 2014, ISSN 1726-6807, http://www.iugaza.edu.ps/ar/periodical/ Parathyroid Hormone, Calcium and Phosphorus Levels in Hemodialysis Patients
More informationVascular calcification in stage 5 Chronic Kidney Disease patients on dialysis
Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Seoung Woo Lee Div. Of Nephrology and Hypertension, Dept. of Internal Medicine, Inha Unv. College of Medicine, Inchon, Korea
More informationPRIMARY HYPERPARATHYROIDISM
PRIMARY HYPERPARATHYROIDISM HYPERPARATHYROIDISM Inappropriate excess secretion of Parathyroid Hormone in Primary Hyperparathyroidism Appropriate Hypersecretion in Secondary Hyperparathyroidism PTH and
More informationComparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients. Int.J.Curr.Res.Aca.Rev.2016; 4(11):
Comparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients Seyed Seifollah Beladi Mousavi 1, Arman Shahriari 2 and Fatemeh Roumi 3 * 1 Department of Nephrology,
More informationCKD-Mineral Bone Disorder (MBD) Pathogenesis of Metabolic Bone Disease. Grants: NIH, Abbott, Amgen, OPKO, Shire
Pathogenesis of Metabolic Bone Disease Stuart M. Sprague, D.O. Chief, Division of Nephrology and Hypertension Professor of Medicine NorthShore University HealthSystem University of Chicago Pritzker School
More informationContents. Authors Name: Christopher Wong: Consultant Nephrologist Anne Waddington: Renal Pharmacist Eimear Fegan : Renal Dietitian
Cheshire and Merseyside Renal Units Guidelines on the Management of Chronic Kidney Disease - Mineral Bone Disorder (adapted from Greater Manchester) Authors Name: Christopher Wong: Consultant Nephrologist
More informationThe elevated parathyroid hormone (PTH) and disordered
Increased Parathyroid Hormone Gene Expression in Secondary Hyperparathyroidism of Experimental Uremia Is Reversed by Calcimimetics: Correlation with Posttranslational Modification of the Trans Acting Factor
More informationSecondary hyperparathyroidism in dialysis patients
Secondary hyperparathyroidism in dialysis patients ( a critical approach of pharmacological treatments) Dominique JOLY Néphrologie Hôpital NECKER, Paris DFG Finn WF. J Am Soc Nephrol. 24;15:271A. Ca ++
More informationNuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416)
Nuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416) Antonio Bellasi, MD, PhD U.O.C. Nefrologia & Dialisi ASST-Lariana, Ospedale S. Anna, Como, Italy Improvement of mineral and bone metabolism
More informationLong-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism
Nephrol Dial Transplant (2009) 24: 982 989 doi: 10.1093/ndt/gfn654 Original Article Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism
More information2.0 Synopsis. Paricalcitol Capsules M Clinical Study Report R&D/15/0380. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-358/Zemplar (paricalcitol) Capsules Name of Active Ingredient: paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For National
More informationCinacalcet treatment in advanced CKD - is it justified?
Cinacalcet treatment in advanced CKD - is it justified? Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia TSN Congress October 21, 2017, Antalya Session Objectives From ROD to
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Prevalence and Pattern of Mineral Bone Disorder in Chronic Kidney Disease Patients Using Serum
More informationComplications of Chronic Kidney Disease: Anemia, Mineral Metabolism, and Cardiovascular Disease
Med Clin N Am 89 (2005) 549 561 Complications of Chronic Kidney Disease: Anemia, Mineral Metabolism, and Cardiovascular Disease Shona Pendse, MD, Ajay K. Singh, MB, MRCP(UK)* Renal Division, Brigham and
More informationPARSABIV (etelcalcetide)
PARSABIV (etelcalcetide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and
More informationPREDICTIVE FACTORS FOR PERSISTENT HYPERPARATHYROIDISM AFTER KIDNEY TRANSPLANTATION
Arch Iranian Med 2005; 8 (4): 295 299 Original Article PREDICTIVE FACTORS FOR PERSISTENT HYPERPARATHYROIDISM AFTER KIDNEY TRANSPLANTATION Gholamhossein Rangbar-Omrani MD *, Mohammad-Hossein Dabbaghmanesh
More informationPhosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis sevelamer hydrochloride, calcium carbonate, and bixalomer
Hemodialysis International 2015; 19:5459 Phosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis sevelamer hydrochloride, calcium carbonate, and bixalomer Toru SANAI, 1
More informationMetabolic Bone Disease Related to Chronic Kidney Disease
Metabolic Bone Disease Related to Chronic Kidney Disease Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic Bone Center Dept of Medicine, Division of Endocrinology Disclosure DSMB member for denosumab
More informationNatpara (parathyroid hormone) Prior Authorization with Quantity Limit Program Summary
Natpara (parathyroid hormone) Prior Authorization with Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Agent Indication Dosing and Administration Natpara (parathyroid hormone) subcutaneous
More informationA Randomised Clinical Study of Alfacalcidol and Paricalcitol
PHD THESIS DANISH MEDICAL JOURNAL A Randomised Clinical Study of Alfacalcidol and Paricalcitol Two vitamin D analogs for treatment of secondary hyperparathyroidism in chronic hemodialysis patients Ditte
More informationNormal kidneys filter large amounts of organic
ORIGINAL ARTICLE - NEPHROLOGY Effect Of Lanthanum Carbonate vs Calcium Acetate As A Phosphate Binder In Stage 3-4 CKD- Treat To Goal Study K.S. Sajeev Kumar (1), M K Mohandas (1), Ramdas Pisharody (1),
More informationRamzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016
Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016 1 MBD + CKD in Elderly patients Our focus for today: CKD
More informationThe secretory response of parathyroid hormone to acute hypocalcemia in vivo is independent of parathyroid glandular sodium/potassium-atpase activity
http://www.kidney-international.org & 211 International Society of Nephrology The secretory response of parathyroid hormone to acute hypocalcemia in vivo is independent of parathyroid glandular sodium/potassium-atpase
More informationParathyroid Hormone: New Assays, New Receptors
Parathyroid Hormone: New Assays, New Receptors By Kevin J. Martin, Irme Akhtar, and Esther A. González Accurate measurements of parathyroid hormone (PTH) in plasma are necessary for the assessment, monitoring,
More informationIpovitaminosi D e metabolismo calcio-fosforo in dialisi peritoneale. Maurizio Gallieni Università degli Studi di Milano
Ipovitaminosi D e metabolismo calcio-fosforo in dialisi peritoneale Maurizio Gallieni Università degli Studi di Milano G Ital Nefrol 2018 - ISSN 1724-5990 Nutrients 2017, 9, 328 Vitamin D deficiency (
More informationPosttransplant Bone Disease. Budapest 2007
Posttransplant Bone Disease Budapest 2007 Post-transplant bone disease 7 10 % of kidney transplanted patients develope a fracture. The risk is higher in postmenopausal female transplanted patients. Diabetic,
More information4/20/2015. The Neck xt Exploration: Intraoperative Parathyroid Hormone (IOPTH) Testing During Surgical Parathyroidectomy. Learning Objectives
The Neck xt Exploration: Intraoperative Parathyroid Hormone (IOPTH) Testing During Surgical Parathyroidectomy Nichole Korpi-Steiner, PhD, DABCC, FACB University of North Carolina Chapel Hill, NC Learning
More informationThe hart and bone in concert
The hart and bone in concert Piotr Rozentryt III Department of Cardiology, Silesian Centre for Heart Disease, Silesian Medical University, Zabrze, Poland Disclosure Research grant, speaker`s fee, travel
More informationCLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015)
CLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015) Dr Simon Steddon, Consultant Nephrologist, Guy s and St Thomas NHS Foundation Trust, London Dr Edward Sharples,
More informationYueming Sun Æ Huihua Cai Æ Jianfeng Bai Æ Hanlin Zhao Æ Yi Miao
World J Surg (2009) 33:1674 1679 DOI 10.1007/s00268-009-0086-3 Endoscopic Total Parathyroidectomy and Partial Parathyroid Tissue Autotransplantation for Patients with Secondary Hyperparathyroidism: A New
More informationCorporate Presentation January 2013
Corporate Presentation January 2013 0 Forward-Looking Statements Certain statements and information included in this presentation are forwardlooking statements under the Private Securities Litigation Reform
More informationORIGINAL ARTICLE. Persistent Parathyroid Hormone Elevation Following Curative Parathyroidectomy for Primary Hyperparathyroidism
Persistent Parathyroid Hormone Elevation Following Curative Parathyroidectomy for Primary Hyperparathyroidism Elizabeth A. Mittendorf, MD; Christopher R. McHenry, MD ORIGINAL ARTICLE Background: Persistent
More informationApproach to a patient with hypercalcemia
Approach to a patient with hypercalcemia Ana-Maria Chindris, MD Division of Endocrinology Mayo Clinic Florida 2013 MFMER slide-1 Background Hypercalcemia is a problem frequently encountered in clinical
More informationSimultaneous Control of PTH and Ca P Is Sustained over Three Years of Treatment with Cinacalcet HCl
Simultaneous Control of PTH and Ca P Is Sustained over Three Years of Treatment with Cinacalcet HCl Stuart M. Sprague,* Pieter Evenepoel, Mario P. Curzi, Maria Teresa González, Fred E. Husserl, Nelson
More information*Correspondence: Masataka Okabe. Tel: Fax: address:
Hypermethylation of the CaSR and VDR genes in the parathyroid glands in chronic kidney disease rats with high phosphate diet Taketo Uchiyama 1, 2, Norifumi Tatsumi 1, Sahoko Kamejima 1, 2, Tsuyoshi Waku
More informationCKD-MBD CKD mineral bone disorder
CKD Renal bone disease Dr Mike Stone University Hospital Llandough Affects 5 10 % of population Increasingly common Ageing, diabetes, undetected hypertension Associated with: Cardiovascular disease Premature
More informationCalcium-Sensing Receptor Expression and Parathyroid Hormone Secretion in Hyperplastic Parathyroid Glands from Humans
Calcium-Sensing Receptor Expression and Parathyroid Hormone Secretion in Hyperplastic Parathyroid Glands from Humans Sagrario Cañadillas,* Antonio Canalejo, Rafael Santamaría, Maria E. Rodríguez,* Jose
More informationHormonalandMineralChangesinEarlyStagesofChronicKidneyDiseases
: F Diseases Volume 16 Issue 2 Version 1.0 Year 2016 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc. (USA) Online ISSN: 2249-4618 & Print ISSN: 0975-5888
More informationORIGINAL ARTICLE. Long-term Results of Subtotal vs Total Parathyroidectomy Without Autotransplantation in Kidney Transplant Recipients
ORIGINAL ARTICLE Long-term Results of Subtotal vs Total Parathyroidectomy Without Autotransplantation in Kidney Transplant Recipients Nada Rayes, MD; Daniel Seehofer, MD; Ralf Schindler, PhD; Petra Reinke,
More informationChronic Kidney Disease-Mineral Bone Disoder: Fibroblast Growth Factor-23 and Phosphate Metabolism
American Medical Journal 4 (1): 105-109, 2013 ISSN 1949-0070 2013 doi:10.3844/amjsp.2013.105.109 Published Online 4 (1) 2013 (http://www.thescipub.com/amj.toc) Chronic Kidney Disease-Mineral Bone Disoder:
More informationCurrent Concepts in the Evaluation and Management of Abnormal Parathyroid Hormone (PTH) Levels Shireen Fatemi, M.D. April, 2012.
Current Concepts in the Evaluation and Management of Abnormal Parathyroid Hormone (PTH) Levels Shireen Fatemi, M.D. April, 2012 Disclosures I have no financial relationships with commercial interests,
More information